Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Triplet combinations in FLT3-mutated AML

Shai Shimony • 13 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia

Shai Shimony , MD, Dana-Farber Cancer Institute, Boston, MA, discusses the efficacy of triplet combinations in FLT3-mutated acute myeloid leukemia (AML), both in the frontline setting and in the relapsed/refractory (R/R) setting. Dr Shimony also highlights the importance of obtaining longer follow-up data on these combinations to better understand durability of response. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Shai Shimony

AML-MR mutations drive the benefit of CPX-351 over 7+3 in the pivotal Phase III AML trial
1:42
AML-MR mutations drive the benefit of CPX-351 over 7+3 in the pivotal Phase III AML trial
Shai Shimony • 8 Dec 2024
The impact of social determinants of health on overall survival in patients with AML
1:45
The impact of social determinants of health on overall survival in patients with AML
Shai Shimony • 8 Dec 2024
Machine learning derived three-parameter prognostic model for survival in patients with BPDCN
2:28
Machine learning derived three-parameter prognostic model for survival in patients with BPDCN
Shai Shimony • 8 Dec 2024
Highlights in AML and MDS from EHA 2022
3:02
Highlights in AML and MDS from EHA 2022
Shai Shimony • 13 Jun 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals